var data={"title":"Amoxicillin and clavulanate: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Amoxicillin and clavulanate: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5632?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=amoxicillin-and-clavulanate-drug-information\" class=\"drug drug_general\">see &quot;Amoxicillin and clavulanate: Drug information&quot;</a> and <a href=\"topic.htm?path=amoxicillin-and-clavulanate-patient-drug-information\" class=\"drug drug_patient\">see &quot;Amoxicillin and clavulanate: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134614\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Augmentin;</li>\n      <li>Augmentin ES-600;</li>\n      <li>Augmentin XR</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134615\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Amoxi-Clav;</li>\n      <li>Apo-Amoxi-Clav;</li>\n      <li>Clavulin;</li>\n      <li>Novo-Clavamoxin;</li>\n      <li>ratio-Aclavulanate</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1045068\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antibiotic, Beta-lactam and Beta-lactamase Combination</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antibiotic, Penicillin</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11432525\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Dosing based on amoxicillin component; dose and frequency are product specific; not all products are interchangeable, using a product with the incorrect amoxicillin:clavulanate ratio could result in subtherapeutic clavulanate concentrations or severe diarrhea.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>General dosing, susceptible infection</b>: Oral: 30 mg amoxicillin/kg/day divided every 12 hours using the 125 mg/5 mL suspension <b>only</b></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1045060\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=amoxicillin-and-clavulanate-drug-information\" class=\"drug drug_general\">see &quot;Amoxicillin and clavulanate: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Note:</b> Dosing based on amoxicillin component; dose and frequency are product specific; not all products are interchangeable; using a product with the incorrect amoxicillin:clavulanate ratio could result in subtherapeutic clavulanic acid concentrations or severe diarrhea.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>General dosing, susceptible infection:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants &lt;3 months: 30 mg amoxicillin/kg/day divided every 12 hours using the 125 mg/5 mL oral suspension <b>only</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants &ge;3 months, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Mild to moderate infection:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Patients weighing &lt;40 kg: <i>Immediate release formulations: </i></p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Twice daily dosing: 25 mg amoxicillin/kg/day in divided doses twice daily using the 200 mg/5 mL or 400 mg/5 mL oral suspension or the 200 mg or 400 mg chewable tablets; maximum single dose: 500 mg amoxicillin</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Three times daily dosing: 20 mg amoxicillin/kg/day in divided doses 3 times daily using the 125 mg/5 mL or 250 mg/5 mL oral suspension; maximum single dose: 500 mg amoxicillin</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Patients weighing &ge;40 kg: <i> Immediate release formulations:</i></p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Twice daily dosing: 500 mg amoxicillin every 12 hours using 500 mg tablet; or if difficulty swallowing, the 125 mg/5 mL or 250 mg/5mL oral suspension may be used</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Three times daily dosing: 250 mg amoxicillin every 8 hours using the 250 mg tablet</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">More severe infection:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Patients weighing &lt;40 kg: <i>Immediate release formulations:</i></p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Twice daily dosing: 45 mg amoxicillin/kg/day in divided doses twice daily using the 200 mg/5 mL or 400 mg/5 mL oral suspension or the 200 mg or 400 mg <b>chewable</b> tablets; maximum single dose: 875 mg amoxicillin</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Three times daily dosing: 40 mg amoxicillin/kg/day in divided doses 3 times daily using the 125 mg/5 mL or 250 mg/5 mL oral suspension; maximum single dose: 500 mg amoxicillin</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Patients weighing &ge;40 kg:</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">\n      <i>Immediate release formulations: </i></p>\n    <p style=\"text-indent:-2em;margin-left:14em;\">Twice daily dosing: 875 mg amoxicillin every 12 hours using the 875 mg tablet, or if difficulty swallowing, the 200 mg/5 mL or the 400 mg/5 mL oral suspension may be used</p>\n    <p style=\"text-indent:-2em;margin-left:14em;\">Three times daily dosing: 500 mg amoxicillin every 8 hours using the 500 mg tablet, or if difficulty swallowing, the 125 mg/5 mL or 250 mg/5mL oral suspension may be used</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">\n      <i> Extended release tablet:</i> 2,000 mg amoxicillin every 12 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Otitis media, acute:</b> Infants &ge;3 months and Children: Oral: 90 mg amoxicillin/kg/day divided every 12 hours for up to 10 days using the 600 mg/5 mL oral suspension <b>only</b> in children with severe illness, who have received amoxicillin in the past 30 days, who have treatment failure at 48 to 72 hours on first-line therapy, and when coverage for &beta;-lactamase positive <i>H. influenzae</i> and <i>M. catarrhalis</i> is needed. Variable duration of therapy; the manufacturer suggests 10-day course in all patients, however new data suggests a shorter-course in some cases: If &lt;2 years of age or severe symptoms (any age): 10-day course; if 2 to 5 years of age with mild to moderate symptoms: 7-day course; if &ge;6 years of age with mild to moderate symptoms: 5- to 7-day course (AAP [Lieberthal 2013]). <b>Note:</b> Per the manufacturer, the 600 mg/5 mL formulation should only be used for patients weighing &lt;40 kg.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Pneumonia, community-acquired: </b> Infants &ge;3 months, Children, and Adolescents: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Manufacturer's labeling:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Patients weighing &lt;40 kg:<i> Immediate release formulations:</i></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Twice daily dosing: 45 mg amoxicillin/kg/day in divided doses twice daily using the 200 mg/5 mL or 400 mg/5 mL oral suspension or the 200 mg or 400 mg chewable tablets; maximum single dose: 875 mg amoxicillin</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Three times daily dosing: 40 mg amoxicillin/kg/day in divided doses 3 times daily using the 125 mg/5 mL or 250 mg/5 mL oral suspension; maximum single dose: 500 mg amoxicillin</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Patients weighing &ge;40 kg:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Immediate release formulations: </i></p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Twice daily dosing: 875 mg amoxicillin every 12 hours using the 875 mg tablet or if difficulty swallowing, the 200 mg/5 mL or the 400 mg/5 mL oral suspension may be used</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Three times daily dosing: 500 mg amoxicillin every 8 hours using the 500 mg tablet or if difficulty swallowing, the 125 mg/5 mL or 250 mg/5mL oral suspension may be used</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Extended release tablet:</i> 2,000 mg amoxicillin every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Alternate dosing: IDSA guidelines; beta-lactamase positive <i>H. influenzae</i> strains (Bradley 2011): <i>Immediate release formulations:</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Standard dose: 45 mg amoxicillin/kg/day in divided doses 3 times daily using the 125 mg/5 mL or 250 mg/5 mL oral suspension formulation; if patient &gt;40 kg, may also use 500 mg tablet; maximum single dose: 500 mg amoxicillin</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">High dose: 90 mg amoxicillin/kg/day in divided doses 2 times daily using the 600 mg/5 mL oral suspension formulation. A wider dosing range of 80 to 100 mg/kg/day divided every 8 hours has also been used (Bradley 2002). <b>Note:</b> Per the manufacturer, the 600 mg/5 mL formulation should only be used for patients weighing &lt;40 kg.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Rhinosinusitis, acute bacterial:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">AAP recommendations (Wald 2013): Children and Adolescents: High-dose: 80 to 90 mg amoxicillin/kg/day divided every 12 hours, maximum dose: 2,000 mg/dose; use the 600 mg/5 mL oral suspension; treatment duration variable: 10 to 28 days, some have suggested discontinuation of therapy 7 days after resolution of signs and symptoms of infection. <b>Note:</b> Recommended for patients with any of the following: Moderate to severe infection, age &lt;2 years, childcare attendance, or recent antibiotic treatment. Per the manufacturer, the 600 mg/5 mL formulation should only be used for patients weighing &lt;40 kg.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IDSA recommendations (Chow 2012): Children and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Patients weighing &lt;40 kg:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Standard dose: <i>Immediate release formulations:</i> 45 mg amoxicillin/kg/day divided every 12 hours for 10 to 14 days using the 200 mg/5 mL or 400 mg/5 mL oral suspension, or the 200 mg and 400 mg <b>chewable</b> tablets formulations <b>only</b></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">High dose (use reserved for select patients; see <b>Note</b>): <i>Immediate release formulations:</i> 90 mg amoxicillin/kg/day divided every 12 hours for 10 to 14 days, using the 600 mg/5 mL oral suspension <b>only</b>; <b>Note:</b> Use recommended in the following: Areas with high endemic rates of penicillin-nonsusceptible <i>S. pneumonia</i>, patients with severe infections, daycare attendance, age &lt;2 years, recent hospitalization, antibiotic use within the past month, patients who are immunocompromised or if initial therapy fails (second-line therapy)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Skin and soft tissue infections, impetigo:</b> Infants &ge;3 months, Children, and Adolescents: Oral: 25 mg amoxicillin/kg/day in divided doses twice daily using the 200 mg/5 mL or 400 mg/5 mL oral suspension or the 200 mg or 400 mg <b>chewable</b> tablets; maximum single dose: 875 mg amoxicillin/dose (IDSA [Stevens 2014])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Streptococci, group A; chronic carrier treatment:</b> Infants &ge;3 months, Children, and Adolescents: Oral: 40 mg amoxicillin/kg/day in divided doses every 8 hours for 10 days using the 125 mg/5 mL or 250 mg/5 mL oral suspension or if patient weighs &ge;40 kg, the 500 mg tablet; maximum single dose: 500 mg amoxicillin (Shulman 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Urinary tract infections:</b> Infants and Children 2 to 24 months: Oral: 20 to 40 mg amoxicillin/kg/day in divided doses 3 times daily using the 125 mg/5 mL or 250 mg/5 mL oral suspension; maximum single dose: 500 mg amoxicillin (AAP 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>Note:</b> Dose is based on the amoxicillin component. Dose and frequency are product specific; not all products are interchangeable. Using a product with the incorrect amoxicillin:clavulanate ratio could result in subtherapeutic clavulanic acid concentrations or severe diarrhea. For adults who have difficulty swallowing the tablets, the 125 mg/5 mL or 250 mg/5 mL suspension may be given in place of the 500 mg/125 mg tablet; the 200 mg/5 mL or 400 mg/5 mL suspension may be given in place of the 875 mg/125 mg tablet.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>General dosing, susceptible infection:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Immediate release: 250 mg every 8 hours <b>or</b> 500 mg every 8 to 12 hours <b>or</b> 875 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Extended release: 2,000 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Rhinosinusitis, acute bacterial:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Immediate release tablet: 500 mg every 8 hours or 875 mg every 12 hours for 5 to 7 days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Extended release tablet: 2,000 mg every 12 hours for 10 days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note:</b> May use high-dose therapy (extended release: 2,000 mg every 12 hours) if initial therapy fails, in areas with high endemic rates of penicillin-nonsusceptible <i>S. pneumoniae</i>, those with severe infections, age &gt;65 years, recent hospitalization, antibiotic use within the past month, or who are immunocompromised (Chow 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Bite wounds (animal/human) or impetigo:</b> Oral: Immediate release: 875 mg every 12 hours; for impetigo, continue for 7 days depending on response (IDSA [Stevens 2014])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Pneumonia, community acquired (CAP):</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Immediate release: 875 mg every 12 hours <b>or</b> 500 mg every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Extended release: 2,000 mg every 12 hours for 7 to 10 days using the 1,000 mg extended release tablet <b>only</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Respiratory tract infections, lower:</b> Oral: Immediate release: 875 mg every 12 hours <b>or</b> 500 mg every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>Streptococci</i>, group A, chronic carrier treatment</b> (IDSA guidelines): Oral: Immediate release: 40 mg amoxicillin/kg/day divided every 8 hours (maximum daily dose: 2,000 mg amoxicillin/<b>day</b>) for 10 days (Shulman 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Dosing adjustment in renal impairment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants, Children, and Adolescents: There are no dosage adjustments provided in the manufacturer's labeling; however, the following guidelines have been used by some clinicians (Aronoff 2007): Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Mild to moderate infection: Dosing based on 20 to 40 mg amoxicillin/kg/day divided every 8 hours or 25 to 45 mg amoxicillin/kg/day divided every 12 hours:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">GFR &gt;30 mL/minute/1.73 m<sup>2</sup>: No adjustment required</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">GFR 10 to 29 mL/minute/1.73 m<sup>2</sup>: 8 to 20 mg amoxicillin/kg/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">GFR &lt;10 mL/minute/1.73 m<sup>2</sup>: 8 to 20 mg amoxicillin/kg/dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Hemodialysis: 8 to 20 mg amoxicillin/kg/dose every 24 hours; give after dialysis</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Peritoneal dialysis: 8 to 20 mg amoxicillin/kg/dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Severe infection (high dose): Dosing based on 80 to 90 mg amoxicillin/kg/day divided every 12 hours:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &gt;30 mL/minute/1.73 m<sup>2</sup>: No adjustment required</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl 10 to 29 mL/minute/1.73 m<sup>2</sup>: 20 mg amoxicillin/kg/dose every 12 hours; do not use the 875 mg tablet</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &lt;10 mL/minute/1.73 m<sup>2</sup>: 20 mg amoxicillin/kg/dose every 24 hours; do not use the 875 mg tablet</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Hemodialysis: 20 mg amoxicillin/kg/dose every 24 hours; give after dialysis; do not use the 875 mg tablet</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Peritoneal dialysis: 20 mg amoxicillin/kg/dose every 24 hours; do not use the 875 mg tablet</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults:<b> Note:</b> Renally adjusted dose recommendations are based on the amoxicillin 250 mg/clavulanate 125 mg and amoxicillin 500 mg/clavulanate 125 mg tablets.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &ge;30 mL/minute: No adjustment required</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 10 to 30 mL/minute: 250 to 500 mg every 12 hours; do not use 875 mg tablet or extended release tablets</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &lt;10 mL/minute: 250 to 500 mg every 24 hours; do not use 875 mg tablet or extended release tablets</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hemodialysis: dialyzable: 250 to 500 mg every 24 hours; administer an additional dose during and after dialysis. Do not use 875 mg tablet or extended release tablets.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling; use with caution. Use contraindicated in patients with a history of amoxicillin and clavulanate-associated hepatic dysfunction.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134591\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Powder for suspension, oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Augmentin:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">125: Amoxicillin 125 mg and clavulanate potassium 31.25 mg per 5 mL (75 mL, 100 mL, 150 mL) [contains potassium 0.16 mEq/5 mL; banana flavor] </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">200: Amoxicillin 200 mg and clavulanate potassium 28.5 mg per 5 mL (50 mL, 75 mL, 100 mL) [contains phenylalanine 7 mg/5 mL and potassium 0.14 mEq/5 mL; orange flavor] [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">250: Amoxicillin 250 mg and clavulanate potassium 62.5 mg per 5 mL (75 mL, 100 mL, 150 mL) [contains potassium 0.32 mEq/5 mL; orange flavor] </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">400: Amoxicillin 400 mg and clavulanate potassium 57 mg per 5 mL (50 mL, 75 mL, 100 mL) [contains phenylalanine 7 mg/5 mL and potassium 0.29 mEq/5 mL; orange flavor] [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Augmentin ES-600:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">600: Amoxicillin 600 mg and clavulanate potassium 42.9 mg per 5 mL (75 mL, 125 mL, 200 mL) [contains phenylalanine 7 mg/5 mL, potassium 0.23 mEq/5 mL; strawberry cream flavor]</p>\n    <p style=\"text-indent:-4em;margin-left:6em;text-align:justify;\">Generic: 200: Amoxicillin 200 mg and clavulanate potassium 28.5 mg per 5 mL (50 mL, 75 mL, 100 mL); 250: Amoxicillin 250 mg and clavulanate potassium 62.5 mg per 5 mL (75 mL, 100 mL, 150 mL); 400: Amoxicillin 400 mg and clavulanate potassium 57 mg per 5 mL (50 mL, 75 mL, 100 mL); 600: Amoxicillin 600 mg and clavulanate potassium 42.9 mg per 5 mL (75 mL, 125 mL, 200 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">Tablet, oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Augmentin:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">250: Amoxicillin 250 mg and clavulanate potassium 125 mg [contains potassium 0.63 mEq/tablet] [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">500: Amoxicillin 500 mg and clavulanate potassium 125 mg [contains potassium 0.63 mEq/tablet]</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">875: Amoxicillin 875 mg and clavulanate potassium 125 mg [contains potassium 0.63 mEq/tablet]</p>\n    <p style=\"text-indent:-4em;margin-left:6em;text-align:justify;\">Generic: 250: Amoxicillin 250 mg and clavulanate potassium 125 mg; 500: Amoxicillin 500 mg and clavulanate potassium 125 mg; 875: Amoxicillin 875 mg and clavulanate potassium 125 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">Tablet, chewable, oral: </p>\n    <p style=\"text-indent:-4em;margin-left:6em;text-align:justify;\">Generic: 200: Amoxicillin 200 mg and clavulanate potassium 28.5 mg [contains phenylalanine]; 400: Amoxicillin 400 mg and clavulanate potassium 57 mg [contains phenylalanine]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, extended release, oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Augmentin XR: 1000: Amoxicillin 1000 mg and clavulanate acid 62.5 mg [contains potassium 12.6 mg (0.32 mEq) and sodium 29.3 mg (1.27 mEq) per tablet; packaged in either a 7-day or 10-day package]</p>\n    <p style=\"text-indent:-4em;margin-left:6em;text-align:justify;\">Generic:  1000: Amoxicillin 1000 mg and clavulanate acid 62.5 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134575\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1045072\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral: Can be given without regard to meals. Administer at the start of a meal to decrease the frequency or severity of GI side effects; may mix with milk, formula, or juice; shake suspension well before use</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134608\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Powder for oral suspension: Store dry powder at or below 25&deg;C (77&deg;F). Reconstituted oral suspension should be kept in refrigerator. Discard unused suspension after 10 days (consult manufacturer's labeling for specific recommendations). Unit-dose antibiotic oral syringes are stable under refrigeration for 24 hours (Tu 1988).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet: Store at or below 25&deg;C (77&deg;F). Dispense in original container. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1045071\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Infections caused by susceptible organisms involving the lower respiratory tract, otitis media, sinusitis, skin and skin structure, and urinary tract; spectrum same as amoxicillin in addition to beta-lactamase producing <i>M. catarrhalis</i>, <i>H. influenzae</i>, <i>N. gonorrhoeae</i>, and <i>S. aureus</i> (excluding MRSA) (FDA approved in all ages)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134644\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Augmentin may be confused with amoxicillin, Azulfidine</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134641\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Dermatologic: Diaper rash, skin rash, urticaria </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Abdominal distress, diarrhea, loose stools, nausea, vomiting </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Genitourinary: Vaginitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Infection: Candidiasis, vaginal mycosis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Rare but important or life-threatening: Cholestatic jaundice, flatulence, headache, hepatic insufficiency, hepatitis, hepatotoxicity (idiosyncratic) (Chalasani, 2014), increased liver enzymes, increased serum alkaline phosphatase, prolonged prothrombin time, thrombocythemia, vasculitis (hypersensitivity)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">Additional adverse reactions seen with <b>ampicillin-class antibiotics:</b> Acute generalized exanthematous pustulosis, agitation, agranulocytosis, anaphylaxis, anemia, angioedema, anxiety, behavioral changes, confusion, convulsions, crystalluria, dental discoloration, dizziness, dyspepsia, enterocolitis, eosinophilia, erythema multiforme, exfoliative dermatitis, gastritis, glossitis, hematuria, hemolytic anemia,  hemorrhagic colitis, hyperactivity, immune thrombocytopenia, increased serum bilirubin, increased serum transaminases, insomnia, interstitial nephritis, leukopenia, melanoglossia, mucocutaneous candidiasis, pruritus, pseudomembranous colitis, serum sickness-like reaction, Stevens-Johnson syndrome, stomatitis, thrombocytopenia, toxic epidermal necrolysis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134598\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to amoxicillin, clavulanic acid, other beta-lactam antibacterial drugs (eg, penicillins, cephalosporins), or any component of the formulation; history of cholestatic jaundice or hepatic dysfunction with amoxicillin/clavulanate potassium therapy</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Augmentin XR: Additional contraindications: Severe renal impairment (creatinine clearance &lt;30 mL/minute) and hemodialysis patients</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Suspected or confirmed mononucleosis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134579\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Anaphylactic/hypersensitivity reactions: Serious and occasionally severe or fatal hypersensitivity (anaphylactic) reactions have been reported in patients on penicillin therapy, especially with a history of beta-lactam hypersensitivity, or history of sensitivity to multiple allergens.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Diarrhea: Incidence of diarrhea is higher than with amoxicillin alone. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic effects: Although rarely fatal, hepatic dysfunction (eg, cholestatic jaundice, hepatitis) has been reported. Patients at highest risk include those with serious underlying disease or concomitant medications. Hepatic toxicity is usually reversible. Monitor liver function tests at regular intervals in patients with hepatic impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Prolonged therapy: Monitor renal, hepatic, and hematopoietic function if therapy extends beyond approved duration times.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment and monitor liver function tests at regular intervals.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Infectious mononucleosis: A high percentage of patients with infectious mononucleosis have developed rash during therapy; ampicillin-class antibiotics not recommended in these patients.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy related issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Clavulanic acid content: Due to differing content of clavulanic acid, not all formulations are interchangeable; use of an inappropriate product for a specific dosage could result in either diarrhea (which may be severe) or subtherapeutic clavulanic acid concentrations leading to decreased clinical efficacy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Phenylalanine: Some products contain phenylalanine.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25819742\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Epstein-Barr virus infection (infectious mononucleosis), acute lymphocytic leukemia, or cytomegalovirus infection increase risk for penicillin-induced maculopapular rash. Appearance of a rash should be carefully evaluated to differentiate a nonallergic ampicillin rash from a hypersensitivity reaction; rash occurs in 5% to 10% of children and is a generalized dull red, maculopapular rash, generally appearing 3 to 14 days after the start of therapy. It normally begins on the trunk and spreads over most of the body. It may be most intense at pressure areas, elbows, and knees. A high percentage (43% to 100%) of patients with infectious mononucleosis have developed rash during therapy; ampicillin-class antibiotics are not recommended in these patients. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298742\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134584\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12639&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Acemetacin: May increase the serum concentration of Penicillins.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Allopurinol: May enhance the potential for allergic or hypersensitivity reactions to Amoxicillin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrexate: Penicillins may increase the serum concentration of Methotrexate. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mycophenolate: Penicillins may decrease serum concentrations of the active metabolite(s) of Mycophenolate. This effect appears to be the result of impaired enterohepatic recirculation. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probenecid: May increase the serum concentration of Penicillins. Management: Avoid the routine use of penicillins and probenecid, but this combination may be used advantageously in select cases with careful monitoring. Monitor for toxic effects of penicillins if probenecid is initiated or the dose is increased.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetracyclines: May diminish the therapeutic effect of Penicillins.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Penicillins may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134587\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134602\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have not been observed in animal reproduction studies. Both amoxicillin and clavulanic acid cross the placenta. Maternal use of amoxicillin/clavulanate has generally not resulted in an increased risk of birth defects. A possible increased risk of necrotizing enterocolitis in neonates or bowel disorders in children exposed to amoxicillin/clavulanate in utero has been observed. In women with acute infections during pregnancy, amoxicillin/clavulanate may be given if an antibiotic is required and appropriate based on bacterial sensitivity; however, use is not recommended in the management of preterm premature rupture of membranes. Oral ampicillin-class antibiotics are poorly absorbed during labor.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1045067\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">With prolonged therapy, monitor renal, hepatic, and hematologic function periodically; monitor for signs of anaphylaxis during first dose</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134578\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Clavulanic acid binds and inhibits beta-lactamases that inactivate amoxicillin resulting in amoxicillin having an expanded spectrum of activity. Amoxicillin inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins (PBPs) which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases) while cell wall assembly is arrested.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134597\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Amoxicillin pharmacokinetics are not affected by clavulanic acid.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Amoxicillin:</b> See individual Amoxicillin monograph. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Clavulanic acid:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Protein binding: ~25%</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Half-life elimination: 1 hour</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Time to peak: 1.5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Excretion: Urine (25% to 40% as unchanged drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1045076\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:0em;display:inline\">Products may not be interchangeable. Both the 250 mg and 500 mg tablets contain the same amount of clavulanic acid; two 250 mg tablets are not equivalent to one 500 mg tablet. Additionally, four 250 mg tablets or two 500 mg tablets are not equivalent to a single 1,000 mg extended release tablet. Based upon usual dosing in pediatric patients &lt;40 kg, typical &quot;TID&quot; regimens provide 5 to 10 mg/kg/day of clavulanate and &quot;BID&quot; regimens 3.4 to 6.4 mg/kg/day.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Some penicillins (eg, carbenicillin, ticarcillin, piperacillin) have been shown to inactivate aminoglycosides <i>in vitro</i>. This has been observed to a greater extent with tobramycin and gentamicin, while amikacin has shown greater stability against inactivation. Concurrent use of these agents may pose a risk of reduced antibacterial efficacy <i>in vivo</i>, particularly in the setting of profound renal impairment. However, definitive clinical evidence is lacking. If combination penicillin/aminoglycoside therapy is desired in a patient with renal dysfunction, separation of doses (if feasible) and routine monitoring of aminoglycoside levels, CBC, and clinical response should be considered.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134601\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Chewable</b> (Amoxicillin-Pot Clavulanate Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200-28.5 mg (20): $56.56</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">400-57 mg (20): $107.81</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension (reconstituted)</b> (Amoxicillin-Pot Clavulanate Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200-28.5 mg/5 mL (100 mL): $36.17</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250-62.5 mg/5 mL (100 mL): $86.43</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">400-57 mg/5 mL (100 mL): $68.93</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">600-42.9 mg/5 mL (125 mL): $83.03</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension (reconstituted)</b> (Augmentin ES-600 Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">600-42.9 mg/5 mL (125 mL): $101.84</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension (reconstituted)</b> (Augmentin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">125-31.25 mg/5 mL (100 mL): $667.44</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250-62.5 mg/5 mL (100 mL): $979.80</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, 12-hour</b> (Amoxicillin-Pot Clavulanate ER Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000-62.5 mg (28): $187.64</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, 12-hour</b> (Augmentin XR Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000-62.5 mg (28): $225.17</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Amoxicillin-Pot Clavulanate Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250-125 mg (30): $177.55</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500-125 mg (20): $75.69</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">875-125 mg (20): $101.03</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Augmentin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500-125 mg (20): $231.49</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">875-125 mg (20): $308.99</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2869364\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Acarbixin (MX);</li>\n      <li>Aclam (ID);</li>\n      <li>Addex (PH);</li>\n      <li>Alvoclav (SG);</li>\n      <li>Ambilan (CL);</li>\n      <li>Amiclav (ID);</li>\n      <li>AMK (HK, TH);</li>\n      <li>Amobay Cl (MX);</li>\n      <li>Amocla (KR);</li>\n      <li>Amoclan (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, TW, YE);</li>\n      <li>Amoclav (DE, IE);</li>\n      <li>Amoksiclav (CN, TH);</li>\n      <li>Amoksixlav (LV);</li>\n      <li>Amoxi Plus (PY);</li>\n      <li>Amoxic Comp (IS);</li>\n      <li>Amoxiclav (LU, MX);</li>\n      <li>Amoxiclav-BID (MX);</li>\n      <li>Amoxiclav-Teva (IL);</li>\n      <li>Amoxicle (KR);</li>\n      <li>Amoxxlin (KR);</li>\n      <li>Amoxyclav (IL);</li>\n      <li>An Qi (CN);</li>\n      <li>Augamox (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Augbidil (VN);</li>\n      <li>AugMaxcil (ZA);</li>\n      <li>Augmentan (DE);</li>\n      <li>Augmentin (AE, AT, AU, BB, BE, BF, BG, BH, BJ, BM, BS, BZ, CH, CI, CN, CR, CY, CZ, EC, EE, EG, ES, ET, FI, FR, GB, GH, GM, GN, GR, GT, GY, HK, HN, HR, HU, IE, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KR, KW, LB, LK, LR, LT, LU, LV, LY, MA, ML, MR, MT, MU, MW, MX, MY, NE, NG, NI, NL, NZ, OM, PA, PE, PK, PL, PT, QA, RO, RU, SA, SC, SD, SI, SK, SL, SN, SR, SV, SY, TH, TN, TR, TT, TZ, UA, UG, UY, VE, VN, YE, ZA, ZM, ZW);</li>\n      <li>Augmentin ES (IL);</li>\n      <li>Augmentin SR (TH);</li>\n      <li>Augmentine (ES);</li>\n      <li>Augmex (VN);</li>\n      <li>Auspilic (ID);</li>\n      <li>Bactiv (PH);</li>\n      <li>Bactoclav (PH);</li>\n      <li>Betaclav (LV);</li>\n      <li>Bioclavid (AE, BH, CY, DE, DK, EG, IQ, IR, JO, KW, LB, LY, OM, PH, QA, SA, SE, SY, YE);</li>\n      <li>Bioclavid Forte (PH);</li>\n      <li>Capsinat (ID);</li>\n      <li>Cavumox (MY, TH);</li>\n      <li>Clacillin Duo Dry Syrup (KR);</li>\n      <li>Clamentin (ZA);</li>\n      <li>Clamixin (ID);</li>\n      <li>Clamodia (VN);</li>\n      <li>Clamovid (HK, MY, SG);</li>\n      <li>Clamox (BD);</li>\n      <li>Clamoxin (MX);</li>\n      <li>Clamoxneo (KR);</li>\n      <li>Clamoxyl (AU);</li>\n      <li>Clamoxyl Duo 400 (AU);</li>\n      <li>Claudia (UA);</li>\n      <li>Clav-K (LK);</li>\n      <li>Clavam (LK, ZW);</li>\n      <li>Clavamel (IE);</li>\n      <li>Clavamox (CH, DE, ID, IN, JP);</li>\n      <li>Clavant (MX);</li>\n      <li>Clavar (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Claventin (IL);</li>\n      <li>Clavicin (MY);</li>\n      <li>Clavinex (CL, EC);</li>\n      <li>Clavipen (MX);</li>\n      <li>Clavmex (PH);</li>\n      <li>Clavodar (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Clavotec (LK);</li>\n      <li>Clavoxil (BR);</li>\n      <li>Clavucyd (MX);</li>\n      <li>Clavulin (BF, BJ, CI, CO, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, MX, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);</li>\n      <li>Clavulin C (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Clavulox Duo (AR, PY);</li>\n      <li>Clavumox (DE, PE, ZA);</li>\n      <li>Clavuser (MX);</li>\n      <li>Coklav (TH);</li>\n      <li>Coyarin (ID);</li>\n      <li>Cramon Duo (KR);</li>\n      <li>Cramotin (KR);</li>\n      <li>Crasigen Duo (KR);</li>\n      <li>Curam (AE, AU, BH, CO, ET, HK, JO, KW, LB, LK, MY, PE, SA, SG, TH, TW, TZ, VN);</li>\n      <li>Danoclav (ID);</li>\n      <li>Darzitil Plus (AR);</li>\n      <li>Duonasa (ES);</li>\n      <li>E-Moxclav (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Enhancin (ET, LK, PH, ZW);</li>\n      <li>Fengkelin (CN);</li>\n      <li>Fleming (HK, TH, VN);</li>\n      <li>Fullicilina Plus (AR);</li>\n      <li>GA-Amclav (AU);</li>\n      <li>Genclav (PH);</li>\n      <li>Germentin (IE);</li>\n      <li>Gimaclav (MX);</li>\n      <li>Haikela (CN);</li>\n      <li>Hibiotic (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Ind Clav (TH);</li>\n      <li>Julmentin (TH);</li>\n      <li>Klamonex (KR);</li>\n      <li>Klamos Forte (ET);</li>\n      <li>Klavic (PH);</li>\n      <li>Kmoxilin (KR);</li>\n      <li>Koact (SG);</li>\n      <li>Koakt (UA);</li>\n      <li>Lansiclav (ID);</li>\n      <li>Luvmox (PH);</li>\n      <li>Moxiclav (AE, BF, BH, BJ, CI, CY, EG, ET, GH, GM, GN, IE, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, QA, SA, SC, SD, SG, SL, SN, SY, TN, TZ, UG, YE, ZM, ZW);</li>\n      <li>Moxicle (TH);</li>\n      <li>Moxilin CV (BD);</li>\n      <li>Moxlin (MX);</li>\n      <li>Myclav (ET, LK, ZW);</li>\n      <li>Natravox (PH);</li>\n      <li>Neoclav (TZ);</li>\n      <li>Novamox (BR);</li>\n      <li>Nufaclav (ID);</li>\n      <li>Okaclav 457 DT (TH);</li>\n      <li>Penhance (PH);</li>\n      <li>pms-Claminat (VN);</li>\n      <li>Quali-Mentin (HK);</li>\n      <li>Ranclav (TH, ZA);</li>\n      <li>Riclasip (MX);</li>\n      <li>Servamox (MX);</li>\n      <li>Sheng Ai (CN);</li>\n      <li>Sinufin (MX);</li>\n      <li>Spektramox (SE);</li>\n      <li>Sullivan (PH);</li>\n      <li>Synclav (TZ);</li>\n      <li>Synermox (NZ);</li>\n      <li>Tedavi (VN);</li>\n      <li>Tyclav (BD);</li>\n      <li>Vestaclav (MY);</li>\n      <li>Viaclav (ID);</li>\n      <li>Viamox (PH);</li>\n      <li>Vulamox (ID)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics, Subcommittee on Urinary Tract Infection, Steering Committee on Quality Improvement and Management, and Roberts KB, &quot;Urinary Tract Infection: Clinical Practice Guideline for the Diagnosis and Management of the Initial UTI in Febrile Infants and Children 2 to 24 Months,&quot; <i>Pediatrics</i>, 2011, 128(3):595-610.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-and-clavulanate-pediatric-drug-information/abstract-text/21873693/pubmed\" target=\"_blank\" id=\"21873693\">21873693</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists (ACOG). Practice bulletin no. 160: premature rupture of membranes. <i>Obstet Gynecol</i>. 2016;127(1):e39-51.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-and-clavulanate-pediatric-drug-information/abstract-text/26695586 /pubmed\" target=\"_blank\" id=\"26695586 \">26695586 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-and-clavulanate-pediatric-drug-information/abstract-text/27060684/pubmed\" target=\"_blank\" id=\"27060684\">27060684</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed. Philadelphia, PA: American College of Physicians; 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Augmentin ES-600 powder (amoxicillin and clavulanate potassium) [prescribing information]. Bridgewater, NJ: Dr Reddys Laboratories Inc; December 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Augmentin tablet (amoxicillin and clavulanate potassium) [prescribing information]. Bridgewater, NJ: Dr Reddys Laboratories Inc; March 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Augmentin XR tablet (amoxicillin and clavulanate potassium) [prescribing information]. Bridgewater, NJ: Dr Reddys Laboratories Inc; April 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Benyamini L, Merlob P, Stahl B, et al, &quot;The Safety of Amoxicillin/Clavulanic Acid and Cefuroxime During Lactation,&quot; <i>Ther Drug Monit</i>, 2005, 27(4):499-502.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-and-clavulanate-pediatric-drug-information/abstract-text/16044108/pubmed\" target=\"_blank\" id=\"16044108\">16044108</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bradley JS, Byington CL, Shah SS, et al, &quot;The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America&quot;, <i>Clin Infect Dis</i>, 2011, 53(7):e25-76.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-and-clavulanate-pediatric-drug-information/abstract-text/21880587/pubmed\" target=\"_blank\" id=\"21880587\">21880587</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bradley JS, &quot;Management of Community-Acquired Pediatric Pneumonia in an Era of Increasing Antibiotic Resistance and Conjugate Vaccines,&quot; <i>Pediatr Infect Dis J</i>, 2002, 21(6):592-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-and-clavulanate-pediatric-drug-information/abstract-text/12182396/pubmed\" target=\"_blank\" id=\"12182396\">12182396</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chalasani NP, Hayashi PH, Bonkovsky HL, et al. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. <i>Am J Gastroenterol</i>. 2014;109(7):950-966.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-and-clavulanate-pediatric-drug-information/abstract-text/24935270/pubmed\" target=\"_blank\" id=\"24935270\">24935270</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chow AW, Benninger MS, Brook I, et al, &quot;IDSA Clinical Practice Guideline for Acute Bacterial Rhinosinusitis in Children and Adults,&quot; <i>Clin Infect Dis</i>, 2012, 54(8):e72-e112.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-and-clavulanate-pediatric-drug-information/abstract-text/22438350/pubmed\" target=\"_blank\" id=\"22438350\">22438350</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-and-clavulanate-pediatric-drug-information/abstract-text/10891521/pubmed\" target=\"_blank\" id=\"10891521\">10891521</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lieberthal AS, Carroll AE, Chonmaitree T, et al, &quot;The Diagnosis and Management of Acute Otitis Media,&quot; <i>Pediatrics</i>, 2013, 131(3):e964-99.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-and-clavulanate-pediatric-drug-information/abstract-text/23439909/pubmed\" target=\"_blank\" id=\"23439909\">23439909</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reed MD, &quot;Clinical Pharmacokinetics of Amoxicillin and Clavulanate,&quot; <i>Pediatr Infect Dis J</i>, 1996, 15(10):949-54.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-and-clavulanate-pediatric-drug-information/abstract-text/8895939/pubmed\" target=\"_blank\" id=\"8895939\">8895939</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shulman ST, Bisno AL, Clegg HW, et al, &quot;Clinical Practice Guideline for the Diagnosis and Management of Group A Streptococcal Pharyngitis: 2012 Update by the Infectious Diseases Society of America,&quot; <i>Clin Infect Dis</i>, 2012.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-and-clavulanate-pediatric-drug-information/abstract-text/22965026/pubmed\" target=\"_blank\" id=\"22965026\">22965026</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2014;59(2):e10-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-and-clavulanate-pediatric-drug-information/abstract-text/24973422/pubmed\" target=\"_blank\" id=\"24973422\">24973422</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Takase Z, Shirafuji H, Uchida M. Clinical and Laboratory Studies on BRL25000 (Clavulanic acid-amoxicillin) in the field of obstetrics and gynecology. <i>Japanese Journal of Chemotherapy </i>1982;30(Suppl 2):579-586.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Todd PA and Benfield P, &quot;Amoxicillin/Clavulanic Acid. An Update of Its Antibacterial Activity, Pharmacokinetic Properties and Therapeutic Use,&quot; <i>Drugs</i>, 1990, 39(2):264-307.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-and-clavulanate-pediatric-drug-information/abstract-text/2184003/pubmed\" target=\"_blank\" id=\"2184003\">2184003</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tu YH, Stiles ML, Allen LV Jr, et al. Stability of amoxicillin trihydrate-potassium clavulanate in original containers and unit dose oral syringes. <i>Am J Hosp Pharm</i>. 1988;45(5):1092-1099.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-and-clavulanate-pediatric-drug-information/abstract-text/3400652/pubmed\" target=\"_blank\" id=\"3400652\">3400652</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wald ER, Applegate KE, Bordley C, et al. Clinical practice guideline for the diagnosis and management of acute bacterial sinusitis in children aged 1-18 years. <i>Pediatrics</i>. 2013;132:e262.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-and-clavulanate-pediatric-drug-information/abstract-text/23796742/pubmed\" target=\"_blank\" id=\"23796742\">23796742</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Weber DJ, Tolkoff-Rubin NE, and Rubin RH, &quot;Amoxicillin and Potassium Clavulanate: An Antibiotic Combination. Mechanism of Action, Pharmacokinetics, Antimicrobial Spectrum, Clinical Efficacy and Adverse Effects,&quot; <i>Pharmacotherapy</i>, 1984, 4(3):122-36.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-and-clavulanate-pediatric-drug-information/abstract-text/6739312/pubmed\" target=\"_blank\" id=\"6739312\">6739312</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the Eleventh WHO Model List of Essential Drugs. 2002. Available at http://www.who.int/maternal_child_adolescent/documents/55732/en/23215911</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12639 Version 141.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F134614\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F134615\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1045068\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11432525\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1045060\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F134591\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F134575\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1045072\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F134608\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1045071\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F134644\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F134641\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F134598\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F134579\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F25819742\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298742\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F134584\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F134587\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F134602\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1045067\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F134578\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F134597\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F1045076\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F134601\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F2869364\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12639|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=amoxicillin-and-clavulanate-drug-information\" class=\"drug drug_general\">Amoxicillin and clavulanate: Drug information</a></li><li><a href=\"topic.htm?path=amoxicillin-and-clavulanate-patient-drug-information\" class=\"drug drug_patient\">Amoxicillin and clavulanate: Patient drug information</a></li></ul></div></div>","javascript":null}